Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
2 hedge funds and large institutions have $2.98M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 210 closing their positions.
68% less call options, than puts
Call options by funds: $16.5M | Put options by funds: $50.7M
99% less funds holding
Funds holding: 214 → 2 (-212)
100% less capital invested
Capital invested by funds: $3.21B → $2.98M (-$3.21B)
100% less funds holding in top 10
Funds holding in top 10: 8 → 0 (-8)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 210
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
CPMG Inc
Dallas,
Texas
|
-$295M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$288M |
| 3 |
BlackRock
New York
|
-$259M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$180M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$152M |
RETA Hedge Fund Activity: Q3 2023 in Review
2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2023, worth a combined $2.98M — down 100% from $3.21B a quarter earlier.
Sellers outnumbered buyers: 210 funds closed out of RETA and 0 opened new positions — a net loss of 210 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was CPMG Inc, exiting entirely with an estimated $295M sold.
- 2 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2023, down from 214 in Q2 2023.
- Funds reported $2.98M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2023 and 210 closed out, a net change of -210 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2023 was CPMG Inc, an estimated $295M sold.
Based on aggregated 13F filings for Q3 2023.